A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
Clinical trial NCT07216703 · RECRUITING
Trial details
- NCT number
- NCT07216703
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2026-01-19
- Primary completion
- 2031-10-29
- Enrollment
- 1023
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.